Edward B. Garon

University of California

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Summary Immune checkpoint inhibitors have revolutionized the treatment of multiple solid malignancies, but their role in the treatment of neuroendocrine neoplasms (NEN) is unclear. The accompanying article reports on a study combining the programmed cell death (PD-1) inhibitor nivolumab with the alkylating agent temozolomide in patients with advanced NENs. See related article by Owen et al., p. 731

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Keunchil Park

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Harry J.M. Groen

Prof.dr.

University Medical Center Groningen

NETHERLANDS

View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Timothy J. Williamson

Assistant Professor

Loyola Marymount University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edward B. Garon

Research Interests

Explore related searches

Contact this professor

Articles (10)

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study.

Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?

cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

Collaborators (4)

Keunchil Park

Harry J.M. Groen

Funda Meric-Bernstam

Timothy J. Williamson

Make your next move.